[68Ga]Ga-NI-FAPI-04 PET/CT scans for tumors, heart disease and pulmonary fibrosis
Tests a PET/CT scan tracer for finding diseases involving activated fibroblasts in adults.
Plain-language title generated from the registry record
Registry title: Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 1/2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Source: NCT07464132, who can take part
Where in China
- Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical CollegeBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Peking Union Medical College Hospital
- Trial code
- NCT07464132
- Record updated
- 11 March 2026
- Original description
The purpose of this study is to conduct clinical research on [68Ga] Ga-NI-FAPI-04 PET/CT imaging and further investigate its diagnostic value in fibroblast activation related diseases.Read full original descriptionShow less
Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases
The purpose of this study is to conduct clinical research on [68Ga] Ga-NI-FAPI-04 PET/CT imaging and further investigate its diagnostic value in fibroblast activation related diseases.
Inclusion: 1: 18-85 years old; 2: Tumor patients can undergo surgery or biopsy to obtain pathological diagnosis; 3: Ability to understand and sign informed consent forms; 4: Expected survival period exceeding 6 months and able to receive follow-up; 5: Healthy volunteers without chronic medical history of hypertension, diabetes, coronary heart disease, kidney disease, tumor, etc.
Exclusion: 1: Pregnant or lactating women; 2: Patients allergic to research drug ingredients; 3: Patients with severe liver and kidney dysfunction (blood creatinine levels exceeding 159 μ mol/L); 4: Patients who participate in other clinical trials and interfere with the results of this study; 5: Patients with severe illness who cannot cooperate with the examination.